Health Care Roundup: Market Talk

Oleh Admin 07 Feb, 2023 Posting Komentar

Updated Feb 6, 2023 5:08 pm ET

1126 HE: AbbVie is looking for a next-generation successor to make up for billions in lost sales due to Humira being targeted by competitors selling high-priced biosimilars. According to AbbVie, the two new immune drugs, Skyrizi and Rinvoq, are more potent than Humira and could surpass Humira's sales peak in four years. Together, the drugs treat the same immune disorders as Humira, such as rheumatoid arthritis, psoriasis, and Crohn's disease. Drugs approved in 2019 generated total sales of approximately $4.6 billion in 2021. Global sales of Humira are expected to fall to $8.2 billion next year and $6.2 billion in 2025, compared with about $21 billion in 2021. AbbVie also has experimental studies on Parkinson's disease. Treatment under regulatory review and therapy in late-stage trials for myelofibrosis and lung cancer. (patrick.sheridan@wsj.com)

1001 ET: Siemens Healthineers' order book is healthy and order growth reassuring in the first quarter of fiscal 2023, analyst Jefferies said in a note. However, staff shortages, increased customer financing and construction costs could exacerbate affordability issues in fiscal 2023, he said. Year-to-date margin expansion could be constrained in the second half as price increases fuel the order book and EBIT margins and currency carryover are expected to decline, Jefferies said. (cecilia.butini@wsj.com)

7:27 am ET - Fleury SA's fourth-quarter results were likely influenced by lower utilization of the medical research firm's services during the period, XP Investimentos analysts Rafael Barros and Raphael Elage said in a note from investigation. Fleury's net profit is likely to improve over the period, helped by acquisitions last year, they said. Lower utilization coupled with a less favorable mix of practices is likely to negatively impact earnings, as are higher interest rates, analysts said. The impact of these factors should be partly offset by a capital increase, XP said. (jeffrey.lewis@wsj.com)

7:15 am ET: Hapvida Participações e Investimentos SA is likely to report negative fourth-quarter results, XP Investimentos analysts Rafael Barros and Raphael Elage said in a research note. Sales were likely to rise in the quarter, helped by net additions to healthcare plans and an increase in average ticket count, but hospital operators' medical loss rates are likely to remain at higher levels. high, as the overall healthcare industry faces higher occupancy rates. say. Hapvida is expected to release its fourth quarter earnings report on February 16. (jeffrey.lewis@wsj.com)

5:08 a.m. ET: Lonza's lower margin guidance for 2023 is partly due to delayed growth plans, but the delays only affected the second quarter and operations are expected to return to normal in the second half, analysts say. 'UBS in a note. Management believes a core EBITDA margin range of 33% to 35% can be achieved by 2024, analysts said after introducing Lonza's CEO and CFO on the tour. According to UBS, demand growth is expected to outpace supply in the next five to seven years. Lonza was down 0.4% at CHF 554.60. (cecilia.butini@wsj.com)

Baca Juga

0448 ET - hVIVO's contract to test RSV vaccine candidate using the Human Challenge test model increases sales transparency until 2024, finnCap said in a memo, after a £6 deal was signed by a research and testing company .8 million with the pharmaceutical giant that signed in the Asia-Pacific region. "As around 95% of our 2023 revenue guidance is already estimated to be contracted and strongly positioned to meet or exceed our fiscal 2023 guidance, this contract increases visibility into revenue in 2024, which we now believe will be around." . 35% of revenue is expected to hold (d around £20m) with management focused on turning back the order book,” analyst Mark Brewer said.